Future directions could involve dual antigen-targeting, IL-15 co-expression61, or combining CLL1CART against JMML with other commonly used treatments in JMML, such as trametinib and azacitidine2. The gene discussed is IL15; the disease is juvenile myelomonocytic leukemia.